Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B.
- Author:
Hua WANG
1
;
Yan-long ZHAO
;
Ke-cheng XU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Capsules; Drug Therapy, Combination; Drugs, Chinese Herbal; therapeutic use; Female; Hepatitis B, Chronic; complications; drug therapy; Humans; Lamivudine; therapeutic use; Liver; drug effects; pathology; virology; Liver Cirrhosis; drug therapy; etiology; Male; Middle Aged; Phytotherapy; Reverse Transcriptase Inhibitors; therapeutic use; Treatment Outcome
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(11):978-980
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic effects of Qianggan Capsule (QC) combined Lamivudine on hepatic fibrosis in patients with chronic hepatitis B.
METHODSEighty-five patients were randomly divided into two groups, group A (40 cases) were treated with QC and Lamivudine and group B (45 cases) were treated with QC alone both for 6 months. Hepatic fibrosis related indexes and pathologic examination of liver biopsy were performed within 3 months before treatment and in 1 month after treatment.
RESULTSSerum levels of hyaluronic acid, collagen N and laminin decreased markedly after treatment in both groups (P < 0.05). Hepatic histopathological examination showed that the total effective rate of impovement in activity of inflammation-necrosis and fibrosis was 80.0% and 70.0% in group A, 57.8% and 75.6% in group B, respectively, the combined treatment showed a better effect in improving the activity of inflammation-necrosis than QC alone (P < 0.05), but with no significant difference to the latter in improving fibrosis.
CONCLUSIONQC combined Lamivudine could markedly reduce the activity of hepatic inflammation-necrosis, QC alone could also improve hepatic fibrosis.
